Abstract: The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject.

Abstract: The present invention relates to a method for inhibiting a cancer metastasis in a subject in need thereof, comprising administering to said subject a cancer metastasis-inhibiting effective amount of: Camphorataimide B; or a composition comprising Camphorataimide B and a pharmaceutically acceptable adjuvant, vehicle, or carrier.

Abstract: The present invention relates to a method for preparing 1,3-cyclohexanedicarboxylic acid capable of exhibiting excellent activity, of enhancing the reaction efficiency and economic efficiency by using a catalyst having improved durability under the reaction conditions of high temperature and strong acid, of achieving excellent conversion rates by allowing most of reactants to participate in the reaction, and of obtaining products having high purity while minimizing by-products within a shorter period of time. The method for preparing 1,3-cyclohexanedicarboxylic acid may include: reducing isophthalic acid in the presence of a metal catalyst fixed to a silica support and containing a palladium (Pd) compound and a copper (Cu) compound in a weight ratio of 1:0.1 to 0.5.

Abstract: It is provided a process for the preparation of bimatoprost, which comprises: a) reacting a compound of formula (III) with ethylamine in the presence of a suitable solvent; and b) deprotecting compound obtained in step a) to obtain bimatoprost, wherein R1 is selected from (C1-C16)alkyl, (C1C16)haloalkyl, (C2-C16)alkenyl, (C2-C16)haloalkenyl, (C1-C16)alkoxy(C1-C16)alkyl, aryl, (C1-C16)alkylaryl, allyl, —(CH2—CH2—O)n—CH3 wherein n=1, 2, 3 or 4, and —CH(O—CH2—CH2)2; R2 is selected from H, (C1-C16)alkyl, (C1-C16)haloalkyl, (C2-C16)alkenyl, (C2-C16)haloalkenyl, (C1-C16)alkoxy(CrC16)alkyl, aryl, (C1-C16)alkylaryl, allyl; or, alternatively, R1 and R2 taken together are selected from —CH2—CH2—CH2—, —CH2—CH2—, —O—CH2—CH2—, and —O—CH?CH—. There are also provided intermediates useful in such preparation process.

Abstract: Compositions including a discontinuous oil phase homogeneously dispersed in a continuous water phase, the oil phase containing a sunscreen agent that includes a polymer composition containing a linear, ultraviolet radiation absorbing polyether, the linear, ultraviolet radiation absorbing polyether including a chemically bound UV-chromophore; and an oil-in water emulsifier component including an anionic oil-in-water emulsifier in an amount such that the composition includes about 0.5 percent by weight to about 3 percent by weight of the anionic oil-in-water emulsifier.

Abstract: A polymer composition comprising a linear ultraviolet radiation absorbing polyether that comprises a chemically bound UV-chromophore.

Abstract: Compositions including a discontinuous oil phase homogeneously dispersed in a continuous water phase, the oil phase including a sunscreen agent that includes a linear, ultraviolet radiation absorbing polyether that comprises a chemically bound UV-chromophore; and an oil-in water emulsifier component including an anionic oil-in-water emulsifier and a nonionic oil-in-water emulsifier having an alcohol functional group, wherein the weight ratio of the anionic oil-in-water emulsifier to the nonionic oil-in-water emulsifier is about 12 or less and wherein the linear, ultraviolet radiation absorbing polyether is present in an amount effective to provide the composition with an SPF of about 10 or greater.

Abstract: Compositions including a discontinuous oil phase homogeneously dispersed in a continuous water phase, the oil phase containing a sunscreen agent that includes a polymer composition containing a linear, ultraviolet radiation absorbing polyether, the linear, ultraviolet radiation absorbing polyether including a chemically bound UV-chromophore; and an oil-in water emulsifier component including an anionic oil-in-water emulsifier in an amount such that the composition includes about 0.5 percent by weight to about 3 percent by weight of the anionic oil-in-water emulsifier.

Abstract: Method for preparing 3,5-dicaffeoylquinic acid and certain derivatives thereof, and use thereof in the preparation of plant-protection products. Method for combating aphids using 3,5-dicaffeoylquinic acid and certain derivatives thereof.

Abstract: A regio-selective and consecutive Michael-Claisen process has been developed for substituted cyclohexane-1,3-dione synthesis started from unsubstituted or substituted acetone and ?,?-unsaturated esters. Substituted cyclohexane-1,3-diones are the basic unit found in several natural products, bioactive alkaloids and acridine dione type heterocycles, polyphenols, and unnatural amino acid synthesis. Most of the potent herbicidal and pesticidal active molecules contain cyclohexane-1,3-dione derivatives. Such an important intermediate synthesis using a facile, atom economy and one-pot process is a demandable area in organic synthesis.

Abstract: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1 —SR2 or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7?, Z, Y, n, y, and x, are as defined herein.

Abstract: A photoalignment compound is represented by the following Chemical Formula 1, wherein “x” represents an integer in a range of 1 to 4, each of R1 and R2 represents —(CH2)n—, “n” represents an integer in a range of 1 to 6, at least one of the (—CH2-)s in R1 is replaceable with R3 represents —(CH2)mCH3, “m” represents an integer in a range of 1 to 12, each hydrogen atom of R3 is replaceable with F or Cl, R4 represents an amino group, aniline group, carboxy group, hydroxyl group, cyano group, alkylene group, or functional groups being represented by the following Chemical Formulas 2, 3, 4, or 5, each hydrogen atom of Chemical Formula 1 is replaceable with —O(CH2)kCH3, —(CH2)kCH3, F, or Cl, and “k” represents an integer in a range of 1 to 3, or 0.

Abstract: The present invention relates to a norbornene monomer, a polynorbornene derivative, a liquid crystal alignment film including the same, and a liquid crystal display device including the same. More particularly, the present invention relates to a norbornene monomer, a polynorbornene derivative, a liquid crystal alignment film including the same, and a liquid crystal display device including the same, which have an alignment property by photoreaction, excellent thermal stability and photoreactivity, the increased photo-reaction rate and reliability of the alignment film, thereby showing high manufacturing process efficiency.

Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.

Abstract: A crosslinkable compound comprising trifluorovinyl has a structure of Formula (I). A method for preparing the crosslinkable compound and a light emitting device prepared from the compound are also disclosed.

Abstract: The invention relates to a process for preparing aryl- and heteroarylacetic acids and derivatives thereof by reaction of aryl or heteroaryl halides with malonic diesters in the presence of a palladium catalyst, of one or more bases and optionally of a phase transfer catalyst. This process enables the preparation of a multitude of functionalized aryl- and heteroarylacetic acids and derivatives thereof, especially also the preparation of arylacetic acids with sterically demanding substituents.

Abstract: A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8?): to the prostaglandin analogue, wherein R3 represents hydrogen or a hydroxyl protecting group.

Abstract: The present invention relates in general to polymer-drug conjugates. In particular, the invention relates to polymer-drug conjugates wherein the conjugated drugs are selected from prostaglandins and substituted prostaglandins, to a method of delivering such prostaglandin drugs to a subject, to a sustained drug delivery system comprising the polymer-drug conjugates, to a method of preparing the polymer-drug conjugates, and to an implant comprising the polymer-drug conjugates. The polymer-drug conjugates may be useful for delivering prostaglandins and substituted prostaglandins for the treatment of glaucoma.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Abstract: The present invention provides novel compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of a compound of the invention to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.

Abstract: Disclosed are hierarchically porous carbon materials with a plurality of discreet nanoparticles dispersed on their carbon phase. The materials possess a continuous network of pores that spans the porous material, permitting the flow of fluids into and through the material. The porous materials can be used as heterogeneous catalysts.

Abstract: Provided is a process for making non-phthalate plasticizers, by acylating an aromatic compound with a succinic anhydride to form a keto-acid, and then esterifying the keto-acid with C4-C13 OXO-alcohols to form a plasticizer compound. The aromatic rings of the aromatic compound may also be optionally hydrogenated.

Abstract: An object of the present invention is to provide an auxin biosynthesis inhibitor superior to L-AOPP. The object can be attained by a compound represented by general formula (I): wherein, R1 to R5 and X are the same as defined in the specification or a salt or solvate thereof.

Abstract: The invention relates to the use of compounds having a monogalactosyldiacylglycerol (MGDG) synthase inhibitory activity as herbicide or algaecide, and to herbicide and algaecide compositions containing at least one of these compounds.

Abstract: The present invention relates to a process for preparing 2-methyl-2?-phenylpropionic acid derivatives showing antihistamine activity in more simplified way, intermediate compounds and their preparation processes used therefor. According to the present invention, pharmaceutically useful 2-methyl-2?-phenylpropionic acid derivatives can be prepared with high yield and purity on industrial scale.

Abstract: The present invention relates to compounds represented by the following Formula I, In Formula I, R1 and R2 are each independently selected from hydrogen, and optionally substituted hydrocarbyl, provided that at least one of R1 and R2 is selected from optionally substituted hydrocarbyl (e.g., tertiary butyl); n is 0, 1 or 2, and each R3 is independently selected from optionally substituted hydrocarbyl; L1 is a divalent linking group, such as a bond or —C(O)O—; each L2 independently represents a flexible segment, such as divalent linear or branched C1-C25 alkyl; each L3 independently represents a rigid segment including, for example, optionally substituted phenylen-1,4-diyl groups; t is from 1 to 4; m and p are each independently from 0 to 4 for each t, provided that the sum of m and p is at least 1 for each t; and E can be, for example, C5-C18 aryl.

Abstract: A catalytic glycosylation method comprising: installing thioether to an anomeric carbon of a carbohydrate; and catalytically activating the thioether with a non-oxophilic Lewis acid. The thioether may comprise an anomerically stable thioether leaving group. The catalytic glycosylation method may further comprise: utilizing an acid-sensitive ester protecting group as permanent protecting group or using a reactivity-based one-pot glycosylation that employs a single-component catalyst to accelerate an oligosaccharide assembly process. A protecting group to mask hydroxyl functionalities in the production of oligosaccharides, natural products or any molecule having a hydroxyl group comprising an acid-labile ester protecting group.

Abstract: A production process for substituted phenylacetic acids or ester analogues thereof is disclosed. In this process toluene or toluene substituted with various substituents, an alcohol, an oxidant and carbon monoxide are used as raw materials to obtain compounds comprising structure of phenylacetic acid ester or analogues thereof by catalysis of the complex catalyst formed from transition metal and ligand, and such compounds are hydrolyzed to obtain various substituted phenylacetic acid based compounds. This type of compounds and their derivatives serve as important fine chemicals used widely in the industries of pharmaceuticals, pesticides, perfume and the like.

Abstract: The present invention relates to novel photoactive polymer materials their use as orienting layer for liquid crystals, which are used for the production of non-structured and structured optical elements or electro-optical elements and multi-layer systems.

Abstract: Disclosed is a method for producing an optically active 2-hydroxy ester, comprising selectively esterifying one enantiomer of a racemic 2-hydroxy ester in a solvent containing a catalyst such as tetramisole or benzotetramisole, and a carboxylic acid anhydride, or a carboxylic acid anhydride and a carboxylic acid. In particular, in the case where the solvent contains a carboxylic acid anhydride, but does not contain a carboxylic acid, as the carboxylic acid anhydride, a carboxylic acid anhydride containing a tertiary or quaternary carbon atom in the a-position is used. On the other hand, in the case where the solvent contains a carboxylic acid anhydride and a carboxylic acid, as the carboxylic acid, a carboxylic acid containing a tertiary or quaternary carbon atom in the a-position is used.

Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are —CH2CH2—. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.

Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.

Abstract: The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production.

Abstract: Processes for preparing water soluble and oil soluble antioxidant compositions extracted together from Labiatae herbs in a single extraction using an alcohol and water solvent, followed by a simple, yet effective purification step that allows the separation of the water soluble antioxidative fractions containing mainly rosmarinic acid from antioxidative fractions containing mainly carnosic acid and carnosol, without cumbersome acid/base partitioning steps.

Abstract: The invention relates to a method of producing optically active 4-chloro-3-hydroxybutanal compound (2) by reacting chloroacetaldehyde with aldehyde compound (1) in the presence of optically active pyrrolidine compound (5). wherein each symbol is as defined in the specification.

Abstract: A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8?): to the prostaglandin analogue, wherein R3 represents hydrogen or a hydroxyl protecting group.

Abstract: The present invention relates to a process for preparing 2-methyl-2?-phenylpropionic acid derivatives showing antihistamine activity in more simplified way, intermediate compounds and their preparation processes used therefore. According to the present invention, pharmaceutically useful 2-methyl-2?-phenylpropionic acid derivatives can be prepared with high yield and purity on industrial scale.

Abstract: The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.

Abstract: A polymerizable liquid crystal compound shown by the following formula, a polymerizable liquid crystal composition that includes the polymerizable liquid crystal compound and a chiral compound polymerizable with the polymerizable liquid crystal compound, a liquid crystalline polymer obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and an optically anisotropic article that includes the liquid crystalline polymer, are disclosed.

Abstract: The present invention relates to the cosmetic, dermatological or pharmaceutical (therapeutic) use of compounds of formula (I) or a cosmetically acceptable salt of a compound of formula (I) or a mixture containing two or more of these compounds or the salts thereof wherein R1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R1 and R2 are covalently bonded to one another, preferably so that a 3 to 8 membered ring is formed, for the lightening of skin and/or hair. The invention further relates to compositions and cosmetic, dermatological or pharmaceutical preparations (compositions) comprising one or more compounds of formula (I) suitable for lightening human skin and/or hair and corresponding methods.

Abstract: The present invention relates to a process for preparing 2-methyl-2?-phenylpropionic acid derivatives showing antihistamine activity in more simplified way, intermediate compounds and their preparation processes used therefor. According to the present invention, pharmaceutically useful 2-methyl-2?-phenylpropionic acid derivatives can be prepared with high yield and purity on industrial scale.

Abstract: A regio-selective and consecutive Michael-Claisen process has been developed for substituted cyclohexane-1,3-dione synthesis started from unsubstituted or substituted acetone and ?,?-unsaturated esters. Substituted cyclohexane-1,3-diones are the basic unit found in several natural products, bioactive alkaloids and acridine dione type heterocycles, polyphenols, and unnatural amino acid synthesis. Most of the potent herbicidal and pesticidal active molecules contain cyclohexane-1,3-dione derivatives. Such an important intermediate synthesis using a facile, atom economy and one-pot process is a demandable area in organic synthesis.

Abstract: The invention relates to a method for producing a cross-coupling product of a benzenoid dizonium salt according to the general formula (I), wherein the groups R1, R2, R3, R4, and R5 represent hydrogen, halogen, an alkyl, alkenyl, aryl, alkoxy, aryloxy, nitro, cyano, hydroxy, acetyl, and/or diazo groups independently of each, and X represents BF4, Cl, F, SO3CH3, CO2CH3, PF6, ClO2CH3, or CIO4, comprising the following steps: (a) providing a benzenoid amide, which with the exception of the diazo function has the same substituents R1, R2, R3, R4, and R5 as the benzenoid diazonium salt of the general formula (I), and hydrolytically cleaving the amide to form an amine or providing a corresponding amine, (b) diazotizing the amine thus obtained or provided with a nitrite, and (c) subsequently reacting the benzenoid diazonium salt with a coupling partner in the presence of a catalyst to form a cross-coupling product, wherein the coupling parter is represented by the general formula (II), R6, R7, and R8 are the same or

Abstract: Provided are compounds of the formula: wherein m=0-3 and n=0-3, and R1 represents CxH2x wherein x=0 to 4 or cyclohexane; R2 represents H, a C1-C6 alkyl group at any of the ortho-, meta- or para-positions, a residue including heteroatoms chosen from O, N, and S, or mixtures thereof; and R3 and R4 represent hydrocarbon residues of OXO-C5-C9 alcohols which are different isomers of equal carbon number or different in carbon number. Also provided are processes for making the compounds and plasticized polymer compositions containing said compounds.

Abstract: The present invention relates to a process for preparing 2-methyl-2?-phenylpropionic acid derivatives showing antihistamine activity in more simplified way, intermediate compounds and their preparation processes used therefor. According to the present invention, pharmaceutically useful 2-methyl-2?-phenylpropionic acid derivatives can be prepared with high yield and purity on industrial scale.

Abstract: A non-aqueous electrolyte additive for a lithium secondary battery, a non-aqueous electrolyte for a lithium secondary battery, and a lithium secondary battery, the additive including a bidentate phosphorus compound represented by the following Chemical Formula 1.

Abstract: A photoalignment compound is represented by the following Chemical Formula 1, wherein “x” represents an integer in a range of 1 to 4, each of R1 and R2 represents —(CH2)n—, “n” represents an integer in a range of 1 to 6, at least one of the (—CH2-)s in R1 is replaceable with R3 represents —(CH2)mCH3, “m” represents an integer in a range of 1 to 12, each hydrogen atom of R3 is replaceable with F or Cl, R4 represents an amino group, aniline group, carboxy group, hydroxyl group, cyano group, alkylene group, or functional groups being represented by the following Chemical Formulas 2, 3, 4, or 5, each hydrogen atom of Chemical Formula 1 is replaceable with —O(CH2)kCH3, —(CH2)kCH3, F, or Cl, and “k” represents an integer in a range of 1 to 3, or 0.

Abstract: The problem of the present invention is provision of a method of producing an n+p-mer oligonucleotide efficiently in a high yield, which includes use of, as a starting material, an n-mer oligonucleotide wherein the 3?-terminal hydroxyl group is protected, and the 5?-terminal hydroxyl group is protected by a temporary protecting group, and continuously performing, in a solution, (1) a deprotection step of the 5?-terminal hydroxyl group, (2) a 5?-terminal elongation step by the addition of a p-mer oligonucleotide wherein the 3?-position is phosphoramidited, and (3) an oxidation step or a sulfurization step of a phosphite triester moiety. It has been found that the above-mentioned problem can be solved by adding a particular cation scavenger during the deprotection step, applying a neutralization treatment after completion of the deprotection reaction, and using a particular oxidizing agent or sulfurizing agent in the oxidation step or sulfurization step.

Abstract: Methods of producing organic materials, and in particular methods of producing petroleum materials and organic compounds such as aromatic acids, phenols, and aliphatic poly-carboxylic acids using an oxidative hydrothermal dissolution (OHD) process are disclosed.

Abstract: The invention relates to novel polyglycerol based UV-filters as well as to topical compositions comprising such novel polyglycerol based UV-filters. Furthermore, the invention relates to the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils.